Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Natural dendritic cell vaccination in chemo-naive metastatic castration-resistant prostate cancer
NL-OMON42196Phase 2Active, not recruiting
- Sponsor
- Tumor Immunologie
- Start
- Sep 2015
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial in prostate cancer (PCa) (2 arms), sponsored by Tumor Immunologie. Primary endpoints: Antitumor immune response in DTH-infiltrating T cells, Type I interferon gene expression in PBMC and 1 more. Started Sep 2015; status: active, not recruiting.
02
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NL-OMON42196.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON42196.